Actively Recruiting

Phase 2
Age: 4Years - 14Years
MALE
NCT05996003

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Led by NS Pharma, Inc. · Updated on 2026-03-06

20

Participants Needed

25

Research Sites

133 weeks

Total Duration

On this page

Sponsors

N

NS Pharma, Inc.

Lead Sponsor

N

Nippon Shinyaku Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.

CONDITIONS

Official Title

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Who Can Participate

Age: 4Years - 14Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 4 years or older and under 15 years
  • Confirmed Duchenne Muscular Dystrophy mutation amenable to exon 44 skipping
  • Able to walk independently without assistive devices
  • Able to complete the time to stand test in under 20 seconds without assistance
  • Stable glucocorticoid dose for at least 3 months and expected to remain stable during the study
  • Other inclusion criteria may apply
Not Eligible

You will not qualify if you...

  • Body weight under 20 kg at consent (for Part 1 screening only)
  • Evidence of symptomatic cardiomyopathy
  • Treatment with anabolic steroids or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose
  • Treatment with any investigational drug within 3 months prior to first dose or within 5 times the drug half-life, whichever is longer
  • Surgery within 3 months prior to first dose or planned during study
  • Previous participation in an interventional study of NS-089/NCNP-02
  • Received exon skipping oligonucleotide within 1 year prior to first dose
  • Other exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 25 locations

1

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

2

Rare Disease Research, LLC - FL

Kissimmee, Florida, United States, 34746

Actively Recruiting

3

Rare Disease Research

Atlanta, Georgia, United States, 30329

Actively Recruiting

4

Ann and Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

5

University of Kansas Medical Center (KUMC)

Kansas City, Kansas, United States, 66160

Actively Recruiting

6

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

7

The Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

8

University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

9

UT Southwestern/Children's Health

Dallas, Texas, United States, 75207

Actively Recruiting

10

Virginia Commonwealth University Health System

Richmond, Virginia, United States, 23298

Actively Recruiting

11

Perth Children's Hospital

Nedlands, Western Australia, Australia, 6009

Not Yet Recruiting

12

Alberta Children's Hospital

Calgary, Alberta, Canada

Not Yet Recruiting

13

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

Not Yet Recruiting

14

London Health Sciences Centre

London, Ontario, Canada

Actively Recruiting

15

Fukui Prefectural Hospital

Fukui-shi, Fukui, Japan, 910-8526

Not Yet Recruiting

16

National Hospital Organization Nagara Medical Center

Nagara, Gifu-shi, Gifu, Japan, 502-8558

Actively Recruiting

17

NHO Osaka Toneyama Medical Center

Toyonaka, Osaka, Japan, 560-8552

Not Yet Recruiting

18

Shiga General Hospital

Moriyama-shi, Shiga, Japan, 524-8524

Not Yet Recruiting

19

National Center of Neurology and Psychiatry

Kodaira, Tokyo, Japan, 187-8551

Not Yet Recruiting

20

Starship Children's Hospital

Auckland, New Zealand, 1023

Not Yet Recruiting

21

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam, South Korea

Not Yet Recruiting

22

Seoul National University Hospital

Seoul, South Korea

Not Yet Recruiting

23

Ankara Bilkent City Hospital

Ankara, Turkey (Türkiye), 06800

Not Yet Recruiting

24

Yeditepe University Kosuyolu Hospital

Istanbul, Turkey (Türkiye), 34718

Not Yet Recruiting

25

S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital

Izmir, Turkey (Türkiye), 11794

Not Yet Recruiting

Loading map...

Research Team

T

Trial info

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here